Salute e Benessere

Electrosurgical Devices Market to Reach USD 10.4 Billion by 2034, Fueled by…

The global electrosurgical devices market is experiencing significant growth, primarily driven by the increasing number of minimally invasive surgeries. These procedures, favored for their reduced recovery times, lower risk of complications, and shorter hospital stays, are becoming more prevalent across various medical specialties, including general surgery, gynecology, urology, and orthopedics. As a result, the demand for advanced electrosurgical devices, which offer precision and efficiency in…
PR Newswire
15/07/2024

Signant Health Appoints 20-Year Life Sciences Veteran Paul Richmond to Executive…

"I am exceptionally pleased to join Signant and lead the commercial team during a time of increased emphasis on the role of emerging biopharma, regulatory focus on patient-reported outcomes, and accelerated adoption of technology throughout the clinical trial lifecycle," said Paul. "Now, more than ever, trial sponsors and CROs look to companies like Signant to ensure data quality through comprehensive and integrated eclinical solutions. Our recent launch of Signant Biotech…
PR Newswire
15/07/2024

In Honor of World Brain Day, the World Federation of Neurology to Host Free…

Organized by the WFN, World Brain Day is an annual global initiative designed to shed light on crucial aspects of brain health. With neurological disorders affecting over 3.40 billion people—and 11.1 million related deaths recorded in 2021 alone—awareness surrounding preventive measures has never been more important. Organized by the WFN, World Brain Day is an annual global initiative designed to shed light on crucial aspects of brain health. With neurological disorders affecting over 3...
PR Newswire
15/07/2024

Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC®

The medication is used in combination with high fluid intake, alkali (low acid), and dietary changes to help prevent the formation of one type (cystine) of kidney stones in certain adult and pediatric patients. The medication is used in combination with high fluid intake, alkali (low acid), and dietary changes to help prevent the formation of one type (cystine) of kidney stones in certain adult and pediatric patients. As a demonstration of its commitment to patients, Endo is offering copay...
PR Newswire
15/07/2024

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic…

"We are very excited to make this strategic investment in MediWound. It aligns with our strategy to bring radical innovations into the wound care space and provide alternative solutions to the more traditional debridement options to improve clinical outcomes and patient experience," said Zlatko Rihter, CEO of Mölnlycke. "This investment will support Mölnlycke's Wound Care mission to 'help free patients from the burden of wounds' and I look forward to this partnership."…
PR Newswire
15/07/2024

Buyback of Class B shares in Essity during week 28, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
15/07/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 15 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
15/07/2024

Food Allergy Market Growth to Continue with a 5.9% CAGR, Reaching USD 69.4…

The growing cases of food intolerance are likely to surge the demand for proper treatments to cure allergies and other disorders. This rising demand is likely to spur opportunities for key players in the industry, fueling the growth of the said sector. The growing cases of food intolerance are likely to surge the demand for proper treatments to cure allergies and other disorders. This rising demand is likely to spur opportunities for key players in the industry, fueling the growth of the said...
PR Newswire
15/07/2024

COSRX Announces Exclusive Deals for Amazon Prime Day 2024 in the UK

Among the highlighted deals are: Among the highlighted deals are: "We are thrilled to participate in Amazon Prime Day, offering our customers exclusive access to some of our most beloved skincare products," said a representative from COSRX. "This is a fantastic opportunity for both our loyal customers and newcomers alike to experience the transformative power of COSRX skincare at unbeatable prices." Prime members can take advantage of these special deals by visiting COSRX's…
PR Newswire
15/07/2024

AstraZeneca Closes Acquisition of Amolyt Pharma

announcedacquisition by the global pharmaceutical company, AstraZeneca, has closed. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH)...
Nasdaq GlobeNewswire
15/07/2024

CMR Surgical appoints Daniel Moore as Non-Executive Chairman

CMR Surgical appoints Daniel Moore as Non-Executive ChairmanMedical technology veteran with over 35 years of senior leadership experience Cambridge, UK – 15 July 2024, 07:00 (BST).CMR Surgical (CMR or 'the Company'), the global surgical robotics business, today announces the appointment of Daniel (Dan) Moore as Non-Executive Chairman of the Board of Directors, effective immediately.Dan Moore is a seasoned executive with over 35 years of both executive and board leadership...
Nasdaq GlobeNewswire
15/07/2024

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Nyxoah Appoints Scott Holstine as Chief Commercial OfficerMont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah...
Nasdaq GlobeNewswire
15/07/2024

Rznomics Inc. Secures Australian Clinical Trial Notification for RHO-targeted…

RZ-004, AAV vector encoding a rhodopsin RNA-targeting trans-splicing ribozyme along with wild type rhodopsin, specifically targets and reprograms pathogenic mutant Rhodopsin mRNA into normal Rhodopsin mRNA, thereby leading to the therapeutic effect. Since RZ-004 targets conservative upstream region of the rhodopsin mutations, all different types of mutations in each patient could be treated with one therapy. RZ-004, AAV vector encoding a rhodopsin RNA-targeting trans-splicing ribozyme along...
PR Newswire
15/07/2024

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of…

The primary endpoint was safety over 52 weeks of study treatment. Octreotide SC depot was well tolerated with a long-term safety profile consistent with that of SoC with first generation somatostatin receptor ligands (SRL), extended-release octreotide and lanreotide, with no new safety signals. The most common adverse events (AEs) were mild to moderate injection site reactions and gastrointestinal events. There were no cases of severe AEs related to octreotide SC depot. One patient had a…
PR Newswire
15/07/2024

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference

Dijon, France, July 15 th2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024. About Crossject Crossject SA...
Nasdaq GlobeNewswire
15/07/2024

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth…

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024- Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the...
Nasdaq GlobeNewswire
15/07/2024

BioSenic S.A. : Transparency notification received from Véronique Pomi  

PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 12, 2024, 6pm CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from Ms Véronique Pomi. The notifications details can be found below and can be consulted on the website of...
Nasdaq GlobeNewswire
12/07/2024

Global Soap and Detergent Market Manufacturers Innovate to Meet Eco-Friendly…

Reports on competitive analyses encompass company overviews, financial performances, product portfolios, and strategies of key players in the Soap & Detergent market. To assess strengths and weaknesses, a comprehensive SWOT analysis was conducted, while a PESTLE analysis was carried out to understand the impact of macroeconomic factors on the market. Also, the report includes detailed analyses of investments made by market players to enhance their global presence. Reports on competitive...
PR Newswire
12/07/2024

Global High-Throughput Screening (HTS) Market to Reach USD 50.2 Billion by 2029…

Browse in-depth TOC on "High-Throughput Screening (HTS) Market". Browse in-depth TOC on "High-Throughput Screening (HTS) Market". 732 - Tables 58 - Figures 577 - Pages Dominance of Consumables Segment in HTS Market In 2023, the consumables segment accounted for the largest share of the global HTS market, driven by the extensive use of reagents and assay kits crucial for HTS processes. The segment's growth is fueled by rising R&D spending among pharmaceutical companies...
PR Newswire
12/07/2024

3D Cell Culture Market to Transcend USD 11.79 Billion Valuation by 2031, Rising…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/3d-cell-culture-market 3D Cell Culture Market Overview: Segments covered in 3D Cell Culture Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/3d-cell-culture-market High Use of Scaffold-based Technology in Regenerative Medicine and Tissue Engineering Applications Growing use of cells in different...
PR Newswire
12/07/2024

PPG Biosensors Market to be dominated by Smartwatches Segment to reach USD…

The information for the PPF Biosensors Market report was collected using primary and secondary research methods, which were combined to make the report reliable. The primary research conducted includes the questionnaire distribution, surveys, and phone interviews with industry experts, market leaders, marketing professionals, and entrepreneurs. The bottom-up methodology has been used to estimate the global and regional market size. SWOT analysis was used to provide the strengths and weaknesses…
PR Newswire
12/07/2024

Endo Files Registration Statement with SEC, Advancing Planned Move to NYSE

Endo anticipates trading of its common stock on the NYSE will begin later in 2024, subject to the SEC declaring the Registration Statement effective and any other required approvals and customary conditions. Endo anticipates trading of its common stock on the NYSE will begin later in 2024, subject to the SEC declaring the Registration Statement effective and any other required approvals and customary conditions. Shares of Endo's common stock currently trade on the OTCQX ®Best Market. U.S...
PR Newswire
12/07/2024

IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis

After giving effect to the Consolidation, the Common Shares were reduced from 13,394,136 to 2,232,357 Common Shares. No fractional Common Shares were issued in connection with the Consolidation. Instead, all fractional Common Shares equal to or greater than one-half resulting from the Consolidation were rounded to the next whole number, otherwise, the fractional Common Share were cancelled. The exercise price and/or conversion price and number of Common Shares issuable under any of the Company's…
PR Newswire
12/07/2024

Charlotte Casebourne Stock moves on from Theolytics to next entrepreneurial…

Mike Grey commented: "On behalf of the board and Theolytics' investors we would like to extend our heartfelt appreciation to Charlotte. Without her, Theolytics wouldn't be in the strong position the company finds itself in today. Under Charlotte's leadership, over $40m of dilutive and non-dilutive capital was raised, and in only seven years the company has advanced into the clinic. We respect her decision to pursue new entrepreneurial endeavors, and wish her the very best. I look forward to…
PR Newswire
12/07/2024
Altri  Comunicati